PT-141

Research Papers and Clinical Trials

The research on PT-141 (bremelanotide) spans several key areas, though detailed study results are not available from the evidence provided.

Clinical Trial Evidence:
Three major clinical trials have been completed examining bremelanotide's effectiveness for female sexual dysfunction. Two Phase 3 trials (NCT02338960 and NCT02333071) specifically evaluated the drug's efficacy and safety in premenopausal women with hypoactive sexual desire disorder (HSDD). An earlier Phase 2 trial (NCT01382719) studied bremelanotide in premenopausal women with both female sexual arousal disorder and HSDD. While these trials are marked as completed, specific sample sizes, methodologies, and results are not detailed in the available evidence.

Academic Research:
Recent publications suggest ongoing interest in bremelanotide's therapeutic applications. A 2026 systematic review examined clinical trial evidence for emerging pharmacological therapies for HSDD in women, which likely included bremelanotide among the treatments analyzed. Another 2026 publication questioned whether bremelanotide should be considered for treating sexual arousal and desire disorders in men, indicating research interest beyond its current approved indication for women.

Additional research has explored bremelanotide within broader contexts, including therapeutic peptides for aesthetic, metabolic, and endocrine conditions, and strategies for treating sexual health concerns after breast and gynecologic cancer treatment.

Evidence Limitations:
The available evidence provides titles and basic trial information but lacks specific details about study methodologies, participant numbers, primary endpoints, or clinical outcomes. More comprehensive data would be needed to fully assess the research foundation for PT-141's therapeutic applications.

This information is for educational purposes only and should not replace consultation with a healthcare provider.